Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review
Open Access
- 1 January 2018
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 10
Abstract
Introduction: Stereotactic body (or ablative) radiotherapy (SBRT/SABR) is now a guideline-recommended treatment for medically inoperable patients with peripherally-located, stage I non-small cell lung cancer (NSCLC), and for medically operable patients who decline surgery. The 5-year local failure rate after SBRT is about 10% and in highly selected patients, surgery has been used as a salvage therapy. We performed a systematic review to address the feasibility, safety, and outcome of salvage surgery for locally recurrent early stage NSCLC after SBRT. Methods: A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed, Embase and Cochrane databases were searched and two authors independently assessed the articles. A total of seven eligible articles were identified. Results: All seven articles were retrospective case series, representing a total of 47 patients. Surgery was completed in all patients. Where reported in sufficient detail, morbidity (four studies) was between 29 and 50% (series of two patients) and 90-day mortality (six studies) was between 0% (four studies) and 11% ( n = 1, disease progression). Median ( n = 5)/mean ( n = 1) reported or calculated follow ups were 7–54.5/17.3 months. Median overall survival was reported in three studies and ranged between 13.6–82.7 months. Crude survival in three others was 2–35 months. Conclusion: Limited, low-level evidence prevents firm conclusions, but based on the existing data, salvage surgery after local recurrence of NSCLC following SBRT appears technically feasible, with acceptable morbidity and mortality in appropriately selected and counselled patients who are fit enough and who accept the risks (level of evidence 4, strength of recommendation C).Keywords
This publication has 31 references indexed in Scilit:
- Ninety-day mortality after resection for lung cancer is nearly double 30-day mortalityThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapyActa Radiologica, 2012
- A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided RadiotherapyJournal of Thoracic Oncology, 2012
- Surgical salvage following stereotactic body radiotherapy for early-stage NSCLCEuropean Respiratory Journal, 2012
- Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?Journal of Thoracic Oncology, 2012
- Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: Outcomes of a markov model analysisRadiotherapy and Oncology, 2011
- Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend AnalysisJournal of Clinical Oncology, 2010
- Surgical Treatment of Local Recurrence After Stereotactic Body Radiotherapy for Primary and Metastatic Lung CancersJournal of Thoracic Oncology, 2010
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009